FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/12/099471 [Registered on: 19/12/2025] Trial Registered Prospectively
Last Modified On: 18/12/2025
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Prospective 
Study Design  Single Arm Study 
Public Title of Study   Evaluation of retinal images taken for the participants and Diabetic Retinopathy AI performance among the new automated non-mydriatic fundus camera and standard fundus camera 
Scientific Title of Study   Evaluation of Retinal Image Quality, Lesion Detection and Diabetic Retinopathy AI Performance Using a New Automated Non-Mydriatic Tabletop Fundus Camera: A Prospective Validation Against a Reference Standard System 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Manavi D Sindal 
Designation  HOD Retina and Vitreous Services 
Affiliation  Aravind Eye Hospital 
Address  Room No. 22, B BLOCK, First floor
Cuddalore main road, Thavalakuppam
Pondicherry
PONDICHERRY
605007
India 
Phone  09884081417  
Fax    
Email  manavi@aravind.org  
 
Details of Contact Person
Scientific Query
 
Name  Dr Manavi D Sindal 
Designation  HOD Retina and Vitreous Services 
Affiliation  Aravind Eye Hospital 
Address  Room No. 22, B BLOCK, First floor
Cuddalore main road, Thavalakuppam

PONDICHERRY
605007
India 
Phone  09884081417  
Fax    
Email  manavi@aravind.org  
 
Details of Contact Person
Public Query
 
Name  Dr Manavi D Sindal 
Designation  HOD Retina and Vitreous Services 
Affiliation  Aravind Eye Hospital 
Address  Room No. 22, B BLOCK, First floor
Cuddalore main road, Thavalakuppam

PONDICHERRY
605007
India 
Phone  09884081417  
Fax    
Email  manavi@aravind.org  
 
Source of Monetary or Material Support  
NIL 
 
Primary Sponsor  
Name  Remidio Innovative Solutions Pvt Ltd 
Address  No, 1-51-2/12, Vacuum Techniques Compound, 1st Cross Rd, Phase-I, Peenya, Bengaluru, Karnataka 560058 
Type of Sponsor  Other [Medical Device ] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Manavi D Sindal  Aravind Eye Hospital  Cuddalore main road Thavalakuppam Pondicherry
Pondicherry
PONDICHERRY 
9884081417

manavi@aravind.org 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee Aravind Eye Hospital  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: H350||Background retinopathy and retinalvascular changes,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Nil  Nil 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  1. All subjects above 18 years of age and ready to give written consent 
 
ExclusionCriteria 
Details  1. significant media opacities (e.g., advanced cataract, corneal opacity)
2. inability to fixate (e.g., nystagmus, amblyopia)
3. active ocular infection or post-operative status
4. hypersensitivity to light, or contraindications to pharmacological dilation (e.g., angle-closure glaucoma)
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Proportion of gradable vs. ungradable images per device
• Level of agreement in image quality between devices
• AI performance metrics per device
• Agreement or discordance in DR detection between devices
• InstaZ performance in retinal lesion detection
• Agreement in gradability pre- vs. post-dilation
• Repeatability of InstaZ image outputs
 
Baseline 
 
Secondary Outcome  
Outcome  TimePoints 
NIL  NIL 
 
Target Sample Size   Total Sample Size="600"
Sample Size from India="600" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   15/01/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
Background

High-quality fundus imaging is critical for effective screening and diagnosis of retinal diseases, particularly diabetic retinopathy. Image quality assessment IQA plays a vital role in ensuring diagnostic accuracy and can be evaluated using both objective device-based and subjective human evaluator-based methods. Subjective assessment remains the most trusted approach, especially since clinical interpretation depends on human review.In this study, we will evaluate and compare the study device against two reference standard non-mydriatic fundus imaging systems

Study device Remidio InstaZ Non-Mydriatic Fundus Camera
Reference standard Topcon NW400 fundus camera system.
Additional Reference Standard device for AI evaluation, objective 2 Remidio Fundus-On-Phone NM10 FOP NM-10

The FOP NM-10 is a compact, smartphone-based, non-mydriatic camera that offers a 40° field of view and is designed for accessibility, ease of use, and cost-effectiveness. It includes an in-built image quality assessor and is equipped with offline AI algorithms for detecting diabetic retinopathy and glaucoma. These AI models have demonstrated strong diagnostic performance, with validated sensitivity and specificity rates of up to 100 percentage, 93.4percentage, and 88.4percentage, 85.4percentage for DR and glaucoma, respectively.
The InstaZ study device, in contrast, is a high-resolution tabletop fundus camera equipped with features such as 3D auto-tracking, auto-capture, and a wider 45 degree field of view. It allows imaging without dilation or dark room conditions and supports imaging enhancing diagnostic versatility. This device does not consists of an inbuilt Artificial Intelligence AI for detecting DR.

The primary objective of the study is to assess and compare the image quality of fundus photographs captured using an automated tabletop non-mydriatic fundus camera Remidio InstaZ and reference standard fundus camera system Topcon NW400. Another primary objective is to evaluate the device agnostic performance of MediosHI DR artificial AI algorithm integrated on FOP NM10 when applied to the novel study device images in diabetic individuals by running the InstaZ images through the same AI algorithm in script form.



Methodology
Consecutive adult patients Greater than 18 years attending the general ophthalmology unit and willing to provide informed consent, will be recruited. Participants must have good fixation and be cooperative during imaging. Exclusion criteria include significant media opacities e.g., advanced cataract, corneal opacity, inability to fixate e.g., nystagmus, amblyopia, active ocular infection or post-operative status, hypersensitivity to light, or contraindications to pharmacological dilation e.g., angle-closure glaucoma.
All participants will undergo a standardized eye examination including history, vision assessment, refraction, slit-lamp evaluation, and dilated fundus examination. Following dilation, all the participants will undergo cataract grading if any using LOCS III classification system by trained ophthalmologist.

 
Close